MicroRNA‑21: A potential therapeutic target in lung cancer (Review)
International Journal of Oncology · 09.07.2025 · 67 (2)
DOI: 10.3892/ijo.2025.5773 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 09.07.2025. Verfasst von Zhouqiang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Second Ward, Department of Respiratory and Critical Care Medicine, Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou, Guangxi 545000, P.R. Ch…. Hauptthemen laut MEDLINE: MicroRNAs, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
In this review, the role of microRNA‑21 (miRNA‑21) as an oncogene in lung cancer was investigated. Studies have shown that miRNA‑21 can promote the progression of lung cancer by targeting downstream target genes, and its expression can be modulated by transcription factors, DNA methylation or competitive endogenous RNA as an upstream regulator. This review highlights that miRNA‑21 can promote the progression of lung cancer through multiple signaling pathways, with a focus on the PI3K/AKT, MEK/ERK, TGF‑β/SMAD, Hippo, NF‑κB and STAT3 signaling pathways. Mechanistically, miRNA‑21 plays an important role in the progression of lung cancer by regulating multiple biological processes, such as proliferation, invasion, metastasis, apoptosis and angiogenesis in lung cancer cells. Higher expression of miRNA‑21 is associated with chemotherapy, radiotherapy and immune resistance in lung cancer. Targeting these molecular pathways may be a novel therapeutic strategy for treating lung cancer. Additionally, miRNA‑21 can serve as a biomarker for lung cancer diagnosis, prognosis and treatment response. This review also summarized the following: i) Current methods employed to inhibit the expression of miRNA‑21 in lung cancer, including CRISPR/Cas9 technology; ii) the application of natural anticancer agents, oligonucleotides, small molecules and miRNA sponges; and iii) the nano‑delivery systems developed for miRNA‑21 inhibitors. Finally, the advancements in research on miRNA mimics and inhibitors in clinical trials, which may promote the application of miRNA‑21 in clinical trials in lung cancer, were discussed. Given that lung cancer is a considerable public health challenge, these studies provide new ways of treating patients with lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Ward, Department of Respiratory and Critical Care Medicine, Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou, Guangxi 545000, P.R. China.
- Department of Traditional Chinese Medicine, Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi 530016, P.R. China.
Zitieren
APA
Li, Z., Zhang, H., Chen, Z., Wu, G., Guo, W., & Li, Y. (2025). MicroRNA‑21: A potential therapeutic target in lung cancer (Review). International Journal of Oncology, 67(2). https://doi.org/10.3892/ijo.2025.5773
Vancouver
Li Z, Zhang H, Chen Z, Wu G, Guo W, Li Y. MicroRNA‑21: A potential therapeutic target in lung cancer (Review). International Journal of Oncology. 2025;67(2). doi:10.3892/ijo.2025.5773
BibTeX
@article{Li2025,
author = {Li, Zhouqiang and Zhang, Hualing and Chen, Zeshan and Wu, Guanzhu and Guo, Weixing and Li, Yun},
title = {MicroRNA‑21: A potential therapeutic target in lung cancer (Review)},
journal = {International Journal of Oncology},
year = {2025},
volume = {67},
number = {2},
doi = {10.3892/ijo.2025.5773}
}
EUVIMED